2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-114506
    trans-​2-​Methoxycinnamic acid 1011-54-7 99.06%
    trans-2-Methoxycinnamic acid (Compound 6) is a trans-cinnamic acid (HY-N0610) derivative. trans-2-Methoxycinnamic acid inhibits α-glucosidase with an IC50 of 4.34 mM. trans-2-Methoxycinnamic acid can be used in the research of HIV infection and hyperglycemia.
    trans-​2-​Methoxycinnamic acid
  • HY-114903
    (E/Z)-BIO-acetoxime 740841-15-0 99.9%
    (E/Z)-BIO-acetoxime (GSK-3 Inhibitor X) is a potent and selective GSK-3α/β inhibitor, with an IC50 of 10 nM. (E/Z)-BIO-acetoxime shows more than 200-flod selectivity over CDK5/p25, CDK2/cyclin A and CDK1/cyclin B (IC50=2.4, 4.3, 63 μM).
    (E/Z)-BIO-acetoxime
  • HY-115363
    Curcumenone 100347-96-4
    Curcumenone is a major constituent of the plants of medicinally important genus of Curcuma. Curcumenone, a caraborane type sesquiterpene has been reported to be a vasorelaxant, hepatoprotective and an effective inhibitor of intoxication.
    Curcumenone
  • HY-115429
    Calcium dextrofolinate 115940-48-2
    Calcium dextrofolinate is a stereoisomer of Calcium folinate. Calcium folinate (Folinic acid calcium) is a biological folic acid and is generally administered along with methotrexate (MTX) as a rescue agent to decrease MTX-induced toxicity.
    Calcium dextrofolinate
  • HY-115575
    tBPC 1942-71-8 98.41%
    tBPC is a selective positive allosteric modulator for human Y4 receptor (Y4R), which enhances the activation of Y4R in G protein signaling and arrestin3 recruitment.
    tBPC
  • HY-115658
    VU0420373 38376-29-3 99.99%
    VU0420373 is a potent heme sensor system (HssRS) activator with an EC50 of 10.7 μM and a pEC50 of 4.97. VU0420373 induces heme biosynthesis, and is toxic to fermenting S. aureus.
    VU0420373
  • HY-116325
    3,5,3'-Triiodo-D-thyronine 5714-08-9
    3,5,3'-Triiodo-D-thyronine, a thyroid hormone, is less effective than 3,5,3'-Triiodo-T-thyronine in normalizing the increased plasma creatine phosphokinase (CPK) activity.
    3,5,3'-Triiodo-D-thyronine
  • HY-118949
    LY255582 119193-09-8 98.0%
    LY255582 is a pan-opioid antagonist and has high affinity for mu, delta, and kappa receptors (Ki: 0.4 nM, 5.2, 2.0 nM respectively). LY255582 can decrease food intake and body weight. LY255582 can be used for the research of obesity.
    LY255582
  • HY-119739
    Skyrin 602-06-2
    Skyrin is an anthraquinone compound that can be isolated from almond fruit. Skyrin is a receptor-selective glucagon antagonist. Skyrin can inhibit the growth of tumor cells.
    Skyrin
  • HY-120958
    Nisinic acid 68378-49-4
    Nisinic acid (C24:6n-3) is a very long chain polyunsaturated fatty acid (VLCPUFA) that is a component of triglycerides and cholesterol esters in mouse and rat testis.
    Nisinic acid
  • HY-121140
    AZ1729 2016864-46-1 99.8%
    AZ1729 is a potent free fatty acid 2 receptor (FFA2) activator, acting as a direct allosteric agonist and as a positive allosteric modulator. AZ1729 increases the activity of the endogenously produced short chain fatty acid propionate in Gi-mediated pathways, but not at those transduced by Gq/G11. AZ1729 induces inhibition of isoproterenol-induced lipolysis in mouse adipocytes. AZ1729 also can Induce migration of human neutrophils. AZ1729 can be used for researching the signaling pathways of the physiological roles of FFA2.
    AZ1729
  • HY-121962
    neo-Inositol 488-54-0 98.0%
    neo-Inositol, a stereoisomer of inositol, has been isolated from calf brain.
    neo-Inositol
  • HY-122482
    β-Rubromycin 27267-70-5
    β-Rubromycin, a quinone antibacterial agent, is a selective HIV-1 reverse transcriptase inhibitor with a Ki of 0.27 μM. β-Rubromycin is a potent telomerase inhibitor with an IC50 of 3 μM. β-Rubromycin inhibits the proliferation of both K-562 and HeLa cells with IC50 values of 19.5 µM and 22.7 µM, respectively.
    β-Rubromycin
  • HY-123481
    JNJ-42253432 1428327-35-8 98.15%
    JNJ-42253432 is a CNS-penetrant, high-affinity and orally active P2X7 antagonist, with pKi values of 9.1 and 7.9 for rat and human P2X7 channels, respectively.
    JNJ-42253432
  • HY-123572
    Bis-T-23 171674-76-3
    Bis-T-23 (AG1717), tyrphostin derivative, is an HIV-I integrase inhibitor. Bis-T-23 can promote actin-dependent dynamin oligomerization. Bis-T-23 can be used for the research of HIV and chronic kidney diseases (CKD).
    Bis-T-23
  • HY-123742
    Estradiol 3-sulfate 17-glucuronide potassium 10392-35-5 99.92%
    Estradiol 3-sulfate 17-glucuronide potassium is metabolite of estradiol. Estradiol 3-sulfate 17-glucuronide potassium inhibits multidrug resistance protein (MRP) mediated 17β -Estradiol 17-(β -D-Glucuronide) transport with a Ki of 22 μM.
    Estradiol 3-sulfate 17-glucuronide potassium
  • HY-124314
    LEI-106 1620582-23-1 99.9%
    LEI-106 is a dual ABHD6 and DAGL-α inhibitor, with a Ki of 0.8 μM for ABHD6, and an IC50 of 18 nM and a Ki of 0.7 μM for DAGL-α. LEI-106 blocks the synthesis of 2-arachidonoylglycerol, reduces the level of endothelial cell-derived 2-arachidonoylglycerol, without altering the levels of cannabinoids and diacylglycerol. LEI-106 is applicable to research related to diet-induced obesity and metabolic syndrome.
    LEI-106
  • HY-124535
    TGX-115 351071-62-0 99.31%
    TGX-115 is a p110β/p110δ-selective, PI3-K inhibitor. TGX-115 blocks p110β-mediated Akt phosphorylation induced by lysophosphatidic acid (LPA) in L6 myotubes, reduces insulin-stimulated PI(3,4)P2 and PIP3 levels in 3T3-L1 adipocytes. TGX-115 can be used for the study of diabetes mellitus.
    TGX-115
  • HY-124803
    GPCR modulator-1 1407592-99-7 98%
    GPCR modulator-1 is a negative allosteric modulator of the GLP-1 receptor (GLP-1R). GPCR modulator-1 can be used for the study of type 2 diabetes.
    GPCR modulator-1
  • HY-125111
    PSB-SB-487 1399049-81-0 98.01%
    PSB-SB-487 is a potent GPR55 antagonist and CB2 agonist with an IC50 value of 0.113 µM for GPR55, and a Ki value of 0.292 µM for human CB2. PSB-SB-487 can be used for researching diabetes, Parkinson’s disease, neuropathic pain, and cancer.
    PSB-SB-487
Cat. No. Product Name / Synonyms Application Reactivity